View printer-friendly version
« Back
February 11, 2007 12:55 p.m.
Shlomo Yanai will assume the role of Teva's President& CEO on March 1st, 2007

Jerusalem, Israel, February 11, 2007 - Further to the company's announcement of October 18, 2006, Mr. Shlomo Yanai will assume the role of President & Chief Executive Officer of Teva Pharmaceutical Industries Ltd. on March 1, 2007. Mr. Shlomo Yanai will succeed Mr. Israel Makov who served as President and Chief Executive Officer for the past five years.

For the past few months, Mr. Yanai has been studying the company as part of the CEO transition process with the outgoing President & CEO, Mr. Israel Makov. Mr. Yanai met with management teams and employees of the group's manufacturing and marketing sites in North America, Europe, Latin America and Israel.

Mr. Eli Hurvitz, Chairman of Teva's Board of Directors, says: "Teva faces a challenging and exciting era, and Shlomo Yanai is the right person to head the company today. Under Yanai's direction, Teva will strengthen its leadership position in the global pharmaceutical market and will reach even greater heights."

"I would like to take this opportunity to thank Israel Makov for his contribution to Teva's sustainable success as the world's number one generic company."

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.




Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic product, Teva's ability to generate revenues and profits closely tied to our success in obtaining U.S. market exclusivity for generic products, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin® and Wellbutrin XL® , the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims which are not covered by insurance, dependence on effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, the difficulty of complex manufacturing of our products and supply delays, environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.